Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis

التفاصيل البيبلوغرافية
العنوان: Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
المؤلفون: Lindsay McCormack, Avik Chatterjee, Jennifer K. Tan, Joseph Ponce
المصدر: JAAD Case Reports
JAAD Case Reports, Vol 10, Iss, Pp 22-24 (2021)
بيانات النشر: Elsevier BV, 2021.
سنة النشر: 2021
مصطلحات موضوعية: medicine.drug_class, suboxone, Case Report, Dermatology, opioid agonists, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, opioid antagonists, Buprenorphine/naloxone, lcsh:Dermatology, medicine, hyperhidrosis, Oxybutynin, chemistry.chemical_classification, Hyperhidrosis, business.industry, opioid use disorder, Opioid use disorder, lcsh:RL1-803, Serotonin reuptake, medicine.disease, oxybutynin, buprenorphine-naloxone, chemistry, Opioid, 030220 oncology & carcinogenesis, Anesthesia, medicine.symptom, business, Opioid antagonist, medicine.drug, Tricyclic
الوصف: Hyperhidrosis occurs when sweating is excessive for thermoregulatory purposes, which may result in decreased quality of life and emotional stress for patients.1 Classified as primary and secondary, secondary hyperhidrosis is often related to an underlying cause.2 Certain medications have been reported to induce hyperhidrosis, including selective serotonin reuptake inhibitors, tricyclic antidepressants, and opioid agonists.2, 3, 4 We present the case of a woman with a history of opioid use disorder who experienced hyperhidrosis in the setting of partial opioid agonist and opioid antagonist therapy (buprenorphine-naloxone), who was treated successfully with oral oxybutynin 5 mg daily.
تدمد: 2352-5126
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ac00720f63e4c300179bcc852ba79c8Test
https://doi.org/10.1016/j.jdcr.2020.12.031Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....3ac00720f63e4c300179bcc852ba79c8
قاعدة البيانات: OpenAIRE